• Sandoz signed a licensing, development, manufacturing, commercialisation deal with mAbxience for a proposed emicizumab biosimilar.
• Agreement gives Sandoz exclusive global commercialisation rights, excluding Argentina, Uruguay, Paraguay; mAbxience will handle development, manufacturing.
• Targets Hemlibra reference market estimated at USD 5.7 billion in global sales; adds Sandoz’s first haemophilia biosimilar.
• Deal expands the biosimilar pipeline to 40 assets; financial terms were not disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2401134_en) on September 18, 2026, and is solely responsible for the information contained therein.